Recipharm

Thrive as Business Development Director at Recipharm!  Are you a seasoned negotiator with a passion for growth? Do you thrive in a dynamic, global environment? Then this Business Development Director role at Recipharm could be perfect for you! Learn more and apply here: https://lnkd.in/dCyfJFh6

How do you mitigate risks and ensure a seamless, robust, and effective tech-transfer? Some of the major risks in a technology transfer are lack of process robustness, clear regulatory strategy and poor project management. At Recipharm we commit to quality across every aspect of your project’s technology transfer. We scale, transfer, and validate processes rapidly by harnessing effective communication, collaboration and process management that mitigate risks, comply with regulations, and uphold our track record for excellence. Trust the Recipharm team to deliver a seamless tech-transfer each and every time. Find out more: https://lnkd.in/dNYR7fap #techtransfer #CDMO 

WEBINAR | Listen to our expert speakers Yves Buelens, Jean-Christophe Moreau and Christophe Schwoehrer explain blow-fill-seal (BFS) technology and the unique benefits of unidose BFS for ophthalmics, biologics and other sterile drug products. Webinar learning objectives: 1. What is BFS technology and the unique benefits of unidose BFS 2. What are the advantages of BFS unidose format in comparison to ocular multidose or glass vial format? 3. How can a CDMO support pharma companies in switching to unidose BFS Watch on demand: https://lnkd.in/d9TRp6ZV

Interest in mRNA technology is higher than ever. However, there are challenges and production bottlenecks that make the scale-up of current mRNA technologies difficult. Could the development of continuous mRNA manufacturing hold the key? In a recent article for DCAT® Value Chain Insights, ReciBioPharm’s Chief Scientific Officer, Aaron B Cowley , explains how ReciBioPharm is working with MIT’s Center for Continuous mRNA Manufacturing to, in his own words, “advance RNA manufacturing far beyond what exists today in the realm of intelligent manufacturing”. Read on to find out more: https://lnkd.in/dY8YyMmD #ContinuousmRNAManufacturing #mRNA #ATMP #MIT #CenterForContinuousmRNAManufacturing

Pioneering Sustainability to elevate Production and Customer Service! The Recipharm Pianezza site in Italy continues to excel in environmental sustainability. I am very excited to announce that we have recently installed and validated a new line dedicated to manufacturing #anesthetic products at our #Pianezza site. Production will commence in the last quarter of the year with a couple of existing customers and more to come soon. This new line is a great example of our commitment to sustainability. By transferring the line from another site, we are not only creating capacity for customers but also reducing the environmental impact of what would have been a disused line. In addition, through collaboration with two main customers on two production lines, we have reviewed production processes which have led to: - 6% reduction in water usage - 60% reduction in greenhouse gas emissions related to these activities - Over 10% reduction in natural gas consumption - Cost savings on water and gas usage - Increased capacity on both lines We are proud of these accomplishments and look forward to continuing our journey towards greater sustainability and efficiency, especially when this means a real “win” for our customers and patients! #AnaestheticProducts #SustainabilityInPharma

Unlocking our sites | With 39 years of experience, our Masate facility is recognised as one of Recipharm's leading sterile manufacturing locations. Supporting over 43 markets worldwide, we take pride in manufacturing more than 80 commercial products, each adhering to the highest quality standards. Specialising in injectables, the facility offers advanced lyophilisation services and liquid filling in vials and ampoules, ensuring tailored solutions for our clients. Discover how we can meet your fill and finish needs, both today and in the future: https://lnkd.in/dTWJ7aAx #CDMO #Sterilefill #Fillfinish #Lyophilization

The global biologics market is growing and developers are exploring alternative container formats for their sterile drug products. As each container format has different characteristics and advantages, careful consideration is required to optimise the performance of biologics products and deliver innovative treatments to patients. In our latest piece with BioProcess International, Vincenza Pironti, Ph.D., MBA Pironti, Head of Business Development at Recipharm explores the key considerations when selecting sterile container formats: https://lnkd.in/dsWQmk6y #BFS #PFS #Fillfinish #Biologics

A pioneering biotech dedicated to developing oncolytic adenovirus therapies had one year to deliver its groundbreaking flagship product to first-in-human clinical trials. Failure to do so risked potential investment consequences and could have prevented the therapy from making it to market. Find out how our experts in oncolytic viruses helped the biotech overcome critical challenges to achieving these accelerated timelines to deliver their therapy on schedule. https://lnkd.in/d7ipxhre #OncolyticViruses #RareDisease #OVManufacturing

Our Pianezza facility plays an important role on the journey to lowering CO2 emissions through innovative e-transport solutions together with, UCB, and their carrier, Green Logistics by Galliker We are very proud that our client chose us to take part in the test run, to transport pharmaceutical products between UCB Farchim SA in Bulle, Switzerland, and Recipharm in Pianezza, Italy, saving an impressive 842 kg of CO2 emissions. This collaboration highlights our shared commitment to reducing CO2 emissions and achieving the goals set as members of the SBT initiative. Read the full article here: https://lnkd.in/dapES4Ni https://lnkd.in/dfU6pRjv

EVENT | We are excited to announce that Balasubramaniam Jagdish, our Vice President of Formulation Development, will be participating in the CRS 2024 Annual Meeting and Expo, which will take place from July 8-12 in Bologna, Italy. Balasubramaniam will be presenting a poster on a case study involving a fixed-dose combination of Ciprofloxacin and Celecoxib as an investigational drug for Amyotrophic Lateral Sclerosis (ALS) patients. He will discuss how Recipharm developed a controlled-release monolithic tablet dosage form consisting of both drugs. We look forward to connecting with other professionals in the field. If you are attending the meeting, please feel free to reach out to Balasubramaniam Jagdish before or during the event. #CSR #formulationdevelopment #OSD #CDMO